Amy J Hill (ANutr)’s Post

#TrendingWithImpact: On March 3, 2024, researchers from Pusan National University published a new research paper in Aging's Volume 16, Issue 5, entitled, “FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.” “This discovery unveils a potential novel molecular target for therapeutic strategies against hepatic steatosis during the aging process [...]” #PressRelease: https://lnkd.in/e4nr7Gyi #aging #hyperlipidemia #steatosis #diet #agingresearch #openaccess #openscience #peerreviewed #journal #publication #publishing #meded

🌟 Exciting News Alert! 🌟 📣 We are thrilled to share that BiOkuris' latest paper, titled "Chitin-glucan improves important pathophysiological features of IBS," has been accepted and published in the esteemed "World Journal of Gastroenterology." 🔍 This groundbreaking study unravels the intricate mechanisms by which Chitin-Glucan (CG) addresses the key pathophysiological aspects of Irritable Bowel Syndrome (IBS), including visceral analgesia, intestinal inflammation, gut barrier function, and toxin chelation. 💊 The findings underscore CG's promise as a novel therapeutic strategy for individuals suffering from IBS or IBS-like symptoms, offering hope for improved management and quality of life. 📚 For the full details of our study, click here ➡️ https://lnkd.in/enmP5jwQ 👏We would like to thank the authors (Caroline Valibouze, Caroline Dubuquoy Bisiaux, Philippe Chavatte, Michaël Génin, Veronique MAQUET, Salvatore Modica Amore, Pierre Desreumaux, Christel Rousseaux) for the high quality and quantity of research that went into this paper and the Service public de Wallonie (Caroline Louis) for their support to fostering innovation. 💪 This milestone represents a significant step forward in our mission to revolutionize gastrointestinal health, and endorses our nomination as a finalist for the most innovative ingredients of the year at Vitafoods Europe. We look forward to continuing our journey towards groundbreaking advancements in the field. Any questions? 📧info@biokuris.com   #IBS #innovation #chitinglucan #gastroenterology

Delving into unmet medical needs in IBS and highlighting our patented technology's ability to address multiple pathways in IBS pathophysiology marks a pivotal stride in our innovation journey. Gratitude to all involved in this research and the creation of this insightful article!

Interesting study exploring the use of non-invasive device for the collection and analysis of intestinal microbiota in post-weaning pigs https://lnkd.in/efNSf_RB

𝗚𝗹𝗼𝗯𝗮𝗹 𝐎𝐫𝐠𝐚𝐧 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 (𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐) The global organ preservation market size reached US$ 187.9 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 313.4 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032. The market is experiencing stable growth driven by increasing prevalence of organ failures due to chronic disorders, such as liver disease, kidney issues, inflammatory bowel disease, and asthma, shortage of donor organs, and the improving healthcare infrastructure. 𝐆𝐫𝐚𝐛 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/gV8wcTJk 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: ●𝐑𝐢𝐬𝐢𝐧𝐠 𝐂𝐡𝐫𝐨𝐧𝐢𝐜 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐁𝐮𝐫𝐝𝐞𝐧: Growing numbers of people with organ-damaging chronic illnesses like COPD and liver disease fuel demand for organ preservation technologies as a potential solution to organ failure. ●𝐋𝐢𝐟𝐞𝐬𝐭𝐲𝐥𝐞 & 𝐃𝐢𝐞𝐭 𝐈𝐦𝐩𝐚𝐜𝐭: Changes in lifestyle and dietary habits contribute to a rise in organ failure, potentially increasing the need for organ preservation methods to extend transplant viability. ●𝐅𝐮𝐭𝐮𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: As chronic obstructive pulmonary disease cases are projected to surge globally, the market for organ preservation solutions may see a corresponding rise to address this growing challenge. 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐒𝐡𝐚𝐩𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐎𝐫𝐠𝐚𝐧 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲: 21st Century Medicine Inc. Biolife Solutions Inc. Bridge to Life Ltd. Bristol Myers Squibb-Myers Dr. Franz Köhler Chemie GmbH Essential Pharmaceuticals, LLC LLC Lifeline Scientific Inc. OrganOx Ltd. Paragonix Technologies, Inc. Inc. TransMedics, Inc. Waters Medical Systems, LLC (an IGL company) Systems LLC XVIVO PERFUSION LUND AB. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/g6ASCEXk #organpreservationmarket #marketresearch #business #marketanalysis #markettrends #researchreport #marketreport #marketforecast #marketgrowth #businessinsights #industryanalysis #marketoutlook #growthprojections #marketstatistics #competitiveanalysis #trendanalysis #marketinsights #imarcgroup

Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study Effect of Postbiotic Bifidobacterium longum CECT 7347 on Digestive Health Study Overview This study evaluated the impact of heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) on digestive symptoms in healthy adults. It was a randomised, double-blind, placebo-controlled trial with 60 participants over 8 weeks, followed by a check-in at week 10. Key Methods Researchers measured: Gastrointestinal symptoms using various scales Gut microbiome changes Biochemical markers and physical measurements Any adverse effects Main Findings The study found: Small changes in digestive symptoms overall A significant reduction in total and non-HDL cholesterol in the HT-ES1 group An increase in beneficial gut bacteria linked to butyrate production Stable levels of faecal calprotectin in the HT-ES1 group, while it increased in the placebo group Conclusions HT-ES1 may support gut health by: Boosting butyrate-producing bacteria Maintaining normal faecal calprotectin levels Lowering serum cholesterol Clinical Implications Clinical trials are essential for creating safe treatments. To make these benefits accessible, we offer DocSym, an AI-driven platform that integrates clinical standards and research for healthcare professionals. Enhancing Healthcare Delivery Our mobile apps streamline operations by: Facilitating scheduling and treatment monitoring Supporting telemedicine This helps clinics improve patient care and reduce paperwork. Discover more at aidevmd.com. https://lnkd.in/g7d_ZP3j #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

A Long-Lasting Solution for IBS 🌟 Building on the groundbreaking results from our initial study published in the American Journal of Gastroenterology, we’re thrilled to share the latest findings from our ongoing research at ENBIOSIS Biotechnology. Our initial results showed that the Enbiosis’ AI-powered Personalized Diet significantly reduced IBS Symptom Severity and enhanced microbiome diversity within just six weeks. Now, the six-month and twelve-month follow-ups have confirmed that these benefits are not only sustained but further solidified over time. Remarkably, while the Personalized Diet group maintained their improvements, those on the FODMAP diet regressed back to baseline IBS symptom severity. These findings highlight the long-term efficacy of the Enbiosis’ AI-based Personalized Diet, offering a sustainable and scientifically validated approach to managing IBS. We’re proud to see our innovative solution delivering not just immediate relief but also enduring benefits. Stay tuned for more insights as we continue to unlock the future of IBS management! #IBS #GutHealth #Microbiome #PersonalizedDiet #ENBIOSIS #HealthTech #Innovation #Gastroenterology #AI #LongTermHealth #DietScience #SustainableHealth

Targeting the Microbiota by Medical Professionals: Where Are We Now? Koen Venema, Beneficial Microbes Consultancy, the Netherlands, shared his insights on the topic during #TargetingMicrobiota2024. Key points covered: 🔹 Gut microbiota’s established role in health and disease 🔹 Challenges in translating microbiota insights into real-life clinical applications 🔹 Large inter-individual differences in microbiota composition, influenced by genetics, diet, and lifestyle 🔹 Functional similarities between individuals despite microbial diversity 🔹 Limited but promising applications like fecal microbiota transplantation for C. difficile infection 🔹 Need for guidance on selecting specific probiotic strains for patients Dr. Venema’s presentation provided a critical overview of the current state of microbiota-targeted approaches in medical practice. #InternationalSocietyofMicrobiota #TargetingMicrobiota #microbiomeresearch #microbiome #microbiota #guthealth

These results are a warning about the long-term effects of 'Elimination Diets.' On the positive side, this is encouraging news for Enbiosis' long-term impact. We are working hard to extend human life and will have more great news soon. For a better future: Enbiosis!.. #integrativehealthpractitioner #integrativehealth #integrativemedicine

Is microbiota characterization a useful tool in clinical practice? In attempt to shed more light on this important issue, researchers from North Zealand University Hospital in Denmark monitored microbiota composition changes in IBS patients undergoing low-FODMAP diet regime or probiotic treatment. Our CE-IVD GA-map® Dysbiosis Test - a standardized and clinically validated microbiota assay - has been used in this study. Read the full article here: https://lnkd.in/dj--dESP #gutmicrobiome #GAmap #research #diagnostics #FODMAP #probiotics